ONC BeiGene, Ltd.

$335.16

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/2/2025

About BeiGene, Ltd.

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Website: https://www.beigene.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1651308
Address
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, KY
Valuation
Market Cap
$26.84B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
7.47
Performance
EPS
$-6.12
Dividend Yield
—
Profit Margin
-16.90%
ROE
-18.80%
Technicals
50D MA
$246.48
200D MA
$207.69
52W High
$287.88
52W Low
$129.96
Fundamentals
Shares Outstanding
99M
Target Price
$330.71
Beta
0.49

ONC EPS Estimates vs Actual

● Estimated
● Actual

ONC News & Sentiment

Sep 02, 2025 • GlobeNewswire NEUTRAL
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
VANCOUVER, British Columbia, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Aug 29, 2025 • Benzinga SOMEWHAT-BULLISH
Why Is BeOne Medicines Stock Gaining Friday? - BeOne Medicines ( NASDAQ:ONC )
Phase 1/2 trial met its primary endpoint, showing strong response rates in mantle cell lymphoma patients. FDA and China's NMPA are reviewing sonrotoclax for potential accelerated approval. Join Benzinga Real-Time Trading Chat Room for 60% Off This Labor Day BeOne Medicines Ltd.
Aug 19, 2025 • GlobeNewswire NEUTRAL
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Aug 19, 2025 • Benzinga NEUTRAL
Zymeworks Announces Participation in Upcoming Investor Conferences - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
Aug 13, 2025 • Motley Fool SOMEWHAT-BULLISH
Indaptus Posts Narrower Loss in Q2
Indaptus Therapeutics ( NASDAQ:INDP ) , a biotechnology company advancing a novel immunotherapy platform for cancer and infectious diseases, reported its second quarter earnings on August 13, 2025. The most significant headline was its narrower-than-expected net loss, reporting a GAAP loss per ...
Aug 11, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Sentiment Snapshot

Average Sentiment Score:

0.105
50 articles with scored sentiment

Overall Sentiment:

Neutral

ONC Reported Earnings

Feb 27, 2025
Dec 31, 2024 (Pre market)
-0.41 Surprise
  • Reported EPS: $-1.43
  • Estimate: $-1.02
  • Whisper: —
  • Surprise %: -40.5%
Nov 12, 2024
Sep 30, 2024 (Pre market)
-0.04 Surprise
  • Reported EPS: $-1.15
  • Estimate: $-1.11
  • Whisper: —
  • Surprise %: -3.2%
Aug 07, 2024
Jun 30, 2024 (Pre market)
0.99 Surprise
  • Reported EPS: $-1.15
  • Estimate: $-2.14
  • Whisper: —
  • Surprise %: 46.3%
May 08, 2024
Mar 31, 2024 (Pre market)
0.13 Surprise
  • Reported EPS: $-2.41
  • Estimate: $-2.54
  • Whisper: —
  • Surprise %: 5.3%
Feb 26, 2024
Dec 31, 2023 (Pre market)
-0.03 Surprise
  • Reported EPS: $-3.48
  • Estimate: $-3.45
  • Whisper: —
  • Surprise %: -0.8%
Nov 10, 2023
Sep 30, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $2.01
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Aug 02, 2023
Jun 30, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-3.64
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
May 04, 2023
Mar 31, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-3.34
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Feb 27, 2023
Dec 31, 2022 (Pre market)
0.0 Surprise
  • Reported EPS: $-4.29
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%

Financials